Mostly considered safe. GI adverse reactions are common but can be minimized with gradual dose titration and eating behavior modification. Ongoing monitoring and evaluation followed by dose adjustments with the patient’s consent based on the patient’s health status would be the clinician’s responsibility.
They are contraindicated in patients with a family history of medullary thyroid carcinoma and/or multiple endocrine neoplasia syndrome type 2, pancreatitis, renal impairment,